Bibliographic Info
GuidelineKey updates to the treatment of drug-resistant tuberculosis: rapid communication, June 2024.
Year of Publication2024
Issuing InstitutionWorld Health Organization
Recommendation
Status
Maintained
Recommended in favor
Conditional
Certainty of evidence
Very low
WHO suggests using the 9-month all-oral regimens (BLMZ, BLLfxCZ and BDLLfxZ) over currently recommended longer (>18 months) regimens in patients with MDR/RR-TB and in whom resistance to fluoroquinolones has been excluded. Amongst these regimens, using BLMZ is suggested over using BLLfxCZ, and BLLfxCZ is suggested over BDLLfxZ
Also Featured In
This recommendation also appears in the following guidelines:
Guideline
WHO consolidated guidelines on tuberculosis: module 4: treatment and care
Year2025
InstitutionWorld Health Organization